Synapse - Komal Jhaveri

Search Within

Komal Lachhman Jhaveri

Results (217)

The genomic landscape of breast cancer in African American women

Meeting Abstract

Serna-Tamayo, C.; Drago, J. Z.; Dos Anjos, C.; Herbert, J.; Pareja, F.; Modi, S.; Jhaveri, K.; Dang, C.; Solit, D. B.; Norton, L.; more...
Cancer Research (2020)

Fulltext@MSK | Save

A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors

Meeting Abstract

Juric, D.; Kalinsky, K.; Oliveira, M.; Cervantes, A.; Bedard, P.; Krop, I.; Hamilton, E.; Schmid, P.; Varga, A.; Turner, N.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Tumor ER protein modulation, molecular characterization and monitoring of cfDNA in phase 1 study of LSZ102 and LSZ102 + ribociclib in patients with ER+ MBC

Meeting Abstract

Jhaveri, K.; Juric, D.; Cresta, S.; Yap, Y. S.; Duhoux, F. P.; Terret, C.; Layman, R.; Balbin, A.; Sheng, Q.; Liao, S.; more...
Cancer Research (2020)

Fulltext@MSK | Save

A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET)

Meeting Abstract

Jhaveri, K.; Juric, D.; Cresta, S.; Yap, Y. S.; Duhoux, F. P.; Terret, C.; Layman, R.; Kundamal, N.; Liao, S.; Ji, Y.; more...
Cancer Research (2020)

Fulltext@MSK | Save

A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2- breast cancer

Meeting Abstract

Jhaveri, K.; Kalinsky, K.; Bedard, P.; Cervantes, A.; Saura, C.; Krop, I.; Hamilton, E.; Schmid, P.; Varga, A.; Turner, N.; more...
Cancer Research (2020)

Fulltext@MSK | Save

A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER(+)) HER2-negative (HER2(-)) metastatic breast cancer

Meeting Abstract

Jhaveri, K.; Winer, E. P.; Lim, E.; Fidalgo, J. A. P.; Bellet, M.; Mayer, I. A.; Boni, V.; Patel, J. M.; Bardia, A.; Garcia, J. M.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Real-world predictors of first-line treatment and descriptive outcomes in HR(+)/HER2(-) metastatic breast cancer patients in the US

Meeting Abstract

Downer, M. K.; Jhaveri, K.; Bardia, A.; Loi, S.; Kent, M.; Luhn, P.; Humke, E. W.
Cancer Research (2020)

Fulltext@MSK | Save

Genomic profiling of primary and metastatic breast cancer in men

Meeting Abstract

Drago, J. Z.; Serna-Tamayo, C.; Dos Anjos, C. H.; Brown, D. N.; Modi, S.; Jhaveri, K.; Solit, D. B.; Traina, T. A.; Chandarlapaty, S.; Reis-Filho, J. S.; more...
Cancer Research (2020)

Fulltext@MSK | Save

ER pathway activity signature as a biomarker for endocrine agent GDC-9545

Meeting Abstract

Daemen, A.; Spoerke, J. M.; Zhou, W.; Guan, J.; Ingalla, E.; Young, A.; Hafner, M.; Aimi, J.; Chang, C. W.; Giltnane, J. M.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET)

Meeting Abstract

Jhaveri, K.; Juric, D.; Yap, Y. S.; Cresta, S.; Layman, R.; Duhoux, F.; Terret, C.; De Vita, S.; Kundamal, N.; He, W.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save